TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15219644
Drug: Fluoxetine (open
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (open label treatment for 6 weeks)
Study: 11705814
Drug: Statin cerivastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin cerivastatin (HMG‐CoA reductase inhibitor)
Study: 9342964
Drug: Once-daily nitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily nitrate therapy
Study: 9342964
Drug: Multiple-dose nitrate
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose nitrate therapy
Study: 3472492
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic applied to the anterior nares
Study: 26657793
Drug: General Practitioner
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Practitioner Treatment as Usual (Control)
Study: 21907756
Drug: Fluoridated milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated milk (2.5 ppm, 5 ppm, 7.5 ppm, 10 ppm, 15 ppm, 20 ppm, 250 ppm) with 25 ml/section and 50 ml/section
Study: 18676140
Drug: Bec2 (2.5mg)/BCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bec2 (2.5mg)/BCG vaccine arm (VA)
Study: 16014329
Drug: Escitalopram 5
Normalized name: escitalopram 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 5 mg
Study: 25733175
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents with stent length < 20 mm
Study: 25733175
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents with stent length ≥ 20 mm
Study: 21194775
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nateglinide and GLP‐1 derivatives
Study: 14550939
Drug: Fluoxetine 10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 10‐20 mg alone
Study: 14550939
Drug: Estradiol patch
Normalized name: Estradiol Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol patch 0.1‐0.2 mg alone
Study: 14550939
Drug: Fluoxetine 10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 10‐20 mg and estradiol patch 0.1‐0.2 mg (combination treatment)
Study: 10441772
Drug: Pharmaceutical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical treatment for osteoporosis
Study: 8537805
Drug: Albuterol 4
Normalized name: albuterol 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 4 mg by mouth three times daily for 7 days
Study: 1794242
Drug: Enoxacin tablets
DrugBank: Enoxacin (DB00467)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enoxacin tablets
Study: 1794242
Drug: Enoxacin capsules
DrugBank: Enoxacin (DB00467)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enoxacin capsules
Study: 31340321
Drug: Lumbar oblique-pulling
Normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar oblique-pulling manipulation in combination with sling-exercise-therapy training
Study: 31340321
Drug: Sling-exercise-therapy training
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sling-exercise-therapy training
Study: 26337246
Drug: Intravenous Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Tranexamic Acid (TXA) administered as a bolus dose of 15 mg/kg 10 minutes before tourniquet inflation and an infusion of 10 mg/kg/h for 3 hours post-operation
Study: 21644186
Drug: Brief strategic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief strategic therapy
Study: 21644186
Drug: Minimal supportive
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal supportive therapy
Study: 11065206
Drug: 5-HT3-receptor antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5-HT3-receptor antagonists
Study: 11065206
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of droperidol and 5-HT3-receptor antagonists
Study: 9302301
Drug: 6.4 mg
Normalized name: menthol 6.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4 mg of zanamivir by intranasal spray plus 10 mg by inhalation
Study: 9302301
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of zanamivir by inhalation
Study: 9302301
Drug: Zanamivir groups
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir groups (both inhaled and intranasal)
Study: 9302301
Drug: Zanamivir (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir (inhaled and intranasal)
Study: 7508055
Drug: Indapamide (IND,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (IND, 2.5 mg/day)
Study: 7508055
Drug: Hydrochlorothiazide (HCTZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ, 25 mg/day)
Study: 7508055
Drug: Nifedipine (NFD,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (NFD, 40 mg/day)
Study: 7508055
Drug: Enalapril (ENL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (ENL, 20 mg/day)
Study: 7508055
Drug: Atenolol (ATL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (ATL, 100 mg/day)
Study: 2834478
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin, fragmine (5,000 anti‐Xa U/24 h)
Study: 2834478
Drug: Standard heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin, calciparin (5,000 IU/8 h)
Study: 2834478
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin, fragmine
Study: 23545929
Drug: 3 new
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 new skin brightener formulations containing SMA‐432
Study: 16984739
Drug: Pycnogenol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (1 mg/kg body weight/day)
Study: 14559692
Drug: Modified FLAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FLAG regimen (n=10): Fludarabine (50 mg/d, VDx5 d) and Ara‐C (200 mg/d, VDx5 or 7 d)
Study: 14559692
Drug: Classic FLAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic FLAG regimen (n=6): Fludarabine (50 mg/d, VDx5d), Ara‐C (500 or 1,000 mg/d, VDx5d) and G‐CSF (300 microg/d, x5 d)
Study: 10691817
Drug: Oxybutynin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin with salivary stimulant pastilles
Study: 24393627
Drug: Oral Health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Health Program (OHP) participation (G1)
Study: 24393627
Drug: No Oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Oral Health Program participation (G2)
Study: 21705063
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment of multiple cardiovascular risk factors
Study: 16530576
Drug: Oral melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral melphalan and prednisone plus thalidomide (MPT)
Study: 16530576
Drug: Oral melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral melphalan and prednisone (MP) alone
Study: 12767550
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg conjugated equine estrogens (CEE)
Study: 12767550
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogens (CEE)
Study: 8334330
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ganciclovir/kg 3 times a week (group A)
Study: 8334330
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg ganciclovir/kg once daily for 5 days a week (group B)
Study: 21186923
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of modafinil (once daily)
Study: 16934861
Drug: Party drug
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Party drug use (alcohol, cannabis, ecstasy, cocaine)
Study: 16934861
Drug: Psychological and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological and social problems related to party drug use
Study: 12063485
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation
Study: 9430602
Drug: Globin digest
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Globin digest 1 g
Study: 9430602
Drug: Globin digest
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Globin digest 4 g
Study: 1907551
Drug: Insulin‐induced hypoglycaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐induced hypoglycaemia with concomitant alpha‐adrenoceptor blockade
Study: 1907551
Drug: Insulin‐induced hypoglycaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐induced hypoglycaemia with total autonomic blockade (alpha‐adrenoceptor blockade combined with beta‐adrenoceptor blockade and atropine)
Study: 1907551
Drug: Insulin‐induced hypoglycaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐induced hypoglycaemia without any autonomic blockade
Study: 21554143
Drug: Alendronate plus
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate plus alfacalcidol (combination therapy)
Study: 21554143
Drug: Alendronate alone
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate alone (monotherapy)
Study: 17237735
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) use
Study: 15017896
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 plus Gemcitabine 1250 mg/m2, day first, and Gemcitabine 1250 mg/m2, day 8, every 3 weeks, total 3 cycles plus fractionated radiation therapy (40-46 Gy) for stage IIIa (N2) and IIIb patients.
Study: 15017896
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 plus Gemcitabine 1250 mg/m2, every three weeks, total 4 cycles without fractionated radiation therapy for stage IV patients.
Study: 11698931
Drug: Probiotic therapy;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic therapy; specific strains not mentioned, dosage and duration not specified.
Study: 27859588
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy and Client-centered therapy
Study: 24947717
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy at discharge (n = 6,873)
Study: 24947717
Drug: No-beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-beta-blocker therapy at discharge (n = 1,637)
Study: 24947717
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy after propensity-score matching (n = 1,325)
Study: 22737708
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol at 320 μg once daily for 6 weeks
Study: 10561182
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (vincristine, dactinomycin, cyclophosphamide, doxorubicin)
Study: 30630790
Drug: Yousiyue (Drospirenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yousiyue (Drospirenone and Ethinylestradiol tablets) plus comprehensive nursing intervention program
Study: 30630790
Drug: General routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: General routine nursing and treatment (Control)
Study: 14716693
Drug: Donepezil (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (2.5-10 mg/day)
Study: 16973667
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg daily for 10 weeks (groups 1 and 2)
Study: 11871208
Drug: Organisational interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Organisational interventions (e.g., central computerised tracking systems, nurses contacting patients)
Study: 11245034
Drug: Intracarotid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracarotid infusion of papaverine and BCNU (250 mg)
Study: 7698589
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg daily)
Study: 31625252
Drug: Haemorrhoid energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemorrhoid energy therapy (HET)
Study: 21635995
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (levodopa 200 mg/benserazide 50 mg)
Study: 21635995
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (branded formulation)
Study: 12616141
Drug: Suppressive valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive valacyclovir therapy
Study: 11206638
Drug: Clarithromycin 100
Normalized name: clarithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 100 mg (group A)
Study: 11206638
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg (group B)
Study: 29695590
Drug: Opicapone 25
Normalized name: opicapone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 25 mg once daily for 1 week, followed by tailored levodopa and/or opicapone dose adjustments
Study: 26985797
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (Eylea) 2 mg every 4 weeks (2q4)
Study: 26985797
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (Eylea) 2 mg every 8 weeks (2q8)
Study: 26985797
Drug: Ranibizumab (Lucentis)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab (Lucentis) 0.5 mg every 4 weeks (Rq4)
Study: 25392635
Drug: Clonidine infusion
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine infusion (group I)
Study: 25392635
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion (group II)
Study: 25392635
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (group III)
Study: 20188604
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G potassium troches (50 mg), applied 4 times per day for 4 days
Study: 8557216
Drug: Terguride (TER)
Normalized name: terguride
DrugBank: Terguride (DB13399)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Terguride (TER) 2 mg/day
Study: 23403883
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose (20 mg iron and 100 μg folic acid)
Study: 23403883
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose doubled (40 mg iron and 200 μg folic acid)
Study: 23403883
Drug: Weekly dose
Normalized name: XPOVIO 60 MG Weekly Dose Carton Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly dose (40 mg iron and 200 μg folic acid)
Study: 20963434
Drug: BG-12 (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG-12 (240 mg orally three times daily for 24 weeks)
Study: 11161392
Drug: Third generation
Normalized name: Third generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third generation chemotherapy regimens
Study: 2890546
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg immediately after dinner
Study: 2890546
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg 3 hours after dinner
Study: 2890546
Drug: famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 40 mg immediately after dinner
Study: 2890546
Drug: famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 40 mg 3 hours after dinner
Study: 30584220
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA 1.8 g/day)
Study: 20574136
Drug: Bezafibrate (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (200-400 mg/day)
Study: 16364159
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 microg once daily
Study: 17640111
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 microg once daily (in subgroup of very severe COPD)
Study: 17640111
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 microg once daily (in subgroup of high healthcare utilization)
Study: 373260
Drug: Cimetidine 1000
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 1000 mg daily for 4 weeks
Study: 11482588
Drug: Health Care
Normalized name: Health Care Lancing Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health Care Financing Administration's pilot Medicare & You 1999 handbook
Study: 2729315
Drug: Bendrofluazide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide + Albuterol
Study: 2729315
Drug: Bendrofluazide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide + Albuterol (Women)
Study: 21256000
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cisplatin plus 5‐fluorouracil (5‐FU) and intravenous ZOL (4 mg, q4 wks) for 3 months
Study: 21256000
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cisplatin plus 5‐fluorouracil (5‐FU) alone
Study: 8884050
Drug: Smokers not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smokers not exposed to chemical compounds
Study: 8884050
Drug: Non-smokers not
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-smokers not exposed to chemical compounds
Study: 1733001
Drug: Other medications
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other medications used commonly for secondary prophylaxis
Study: 6704282
Drug: Nifedipine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (single sublingual dose)
Study: 31416472
Drug: Post-treatment period
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment period (6h after treatment)
Study: 29960852
Drug: KetoCal® (4:1
Approvals — FDA: no, EMA: no, PMDA: no
Description: KetoCal® (4:1 ketogenic ratio formula), 8-ounce (237 mL) daily for the first month
Study: 20188444
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (vancomycin 1g every 12h or antistaphylococcal penicillin 2g every 4h, both with gentamicin 1mg/kg every 8h for the first 4 days)
Study: 17659004
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg oral Polypodium leucotomos three times daily with NB-UVB twice weekly
Study: 17659004
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with NB-UVB twice weekly
Study: 16195287
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 600 microg
Study: 8615488
Drug: Dimenhydrinate 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimenhydrinate 0.5 mg/kg intravenously
Study: 6146006
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir 200 mg four times a day
Study: 30640697
Drug: Intravenous oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous oxaliplatin 75 mg/m2 on day 1 and intraperitoneal docetaxel 75 mg/m2 on day 2
Study: 27812501
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture plus fluoxetine
Study: 27812501
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture plus fluoxetine
Study: 20200268
Drug: Sergliflozin etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sergliflozin etabonate 500 mg
Study: 20200268
Drug: Sergliflozin etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sergliflozin etabonate 1000 mg
Study: 20200268
Drug: Sergliflozin etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sergliflozin etabonate 500 or 1000 mg
Study: 15657326
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (E + P), given as CEE plus 2.5 mg/d of medroxyprogesterone acetate
Study: 10492316
Drug: Subcutaneous calcium-heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous calcium-heparin (12,500 IU/day)